William Blair Analysts Boost Earnings Estimates for LENZ

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - William Blair lifted their Q2 2025 earnings per share estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Thursday, May 8th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.66) per share for the quarter, up from their prior estimate of ($0.69). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics' Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($2.80) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.67) EPS.

Several other equities analysts also recently commented on the company. Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 target price for the company. Citigroup lifted their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, May 8th. Finally, TD Cowen started coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $46.60.

LENZ Therapeutics Trading Down 4.6%

LENZ traded down $1.33 during midday trading on Monday, reaching $27.63. The company's stock had a trading volume of 131,801 shares, compared to its average volume of 186,009. The stock has a market cap of $777.67 million, a P/E ratio of -15.61 and a beta of 0.41. The company has a fifty day simple moving average of $24.82 and a 200 day simple moving average of $27.33. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02.

Hedge Funds Weigh In On LENZ Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of LENZ Therapeutics by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 1,199,462 shares of the company's stock worth $30,838,000 after purchasing an additional 21,015 shares during the period. Price T Rowe Associates Inc. MD increased its stake in LENZ Therapeutics by 83.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock valued at $23,760,000 after acquiring an additional 374,326 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in LENZ Therapeutics during the fourth quarter valued at about $22,243,000. Alyeska Investment Group L.P. boosted its position in LENZ Therapeutics by 16.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company's stock valued at $4,103,000 after buying an additional 20,000 shares during the period. Finally, Northern Trust Corp boosted its position in LENZ Therapeutics by 7.4% during the fourth quarter. Northern Trust Corp now owns 139,288 shares of the company's stock valued at $4,021,000 after buying an additional 9,649 shares during the period. Institutional investors and hedge funds own 54.32% of the company's stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.